1.
|
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: UHW-AML16, EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLO34100405, NCT00317642
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: NCI, Other
Protocol IDs: TOTXVI, NCT00549848
|
|
4.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: NCI, Other
Protocol IDs: AML08, NCT00703820
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 21
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLO21800205, NCT00315705
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 2 and over
Sponsor: NCI
Protocol IDs: MSKCC-06065, NCT00416351
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Under 55
Sponsor: NCI
Protocol IDs: MSKCC-06125, NCT00423514
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 and over
Sponsor: Other
Protocol IDs: 2005-0552, NCT00412243
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 1066306 (0408), NCT00156013
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: Other
Protocol IDs: CHNY-06-532, AAAC0918, NCT00529360
|
|
11.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: NCI
Protocol IDs: UWCC-6562, FHCRC- 6562, UWCC-UW 6562, UWCC-07-9655-H/A, NCT00602225
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 25223, PSU25223, NCT00626626
|
|
13.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 07-401, NCT00644189
|
|
14.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 89
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: OHSU-HEM-07156-L, HEM-07156-L, IRB#4101, GENZYME-OHSU-HEM-07156-L, NCT00691652
|
|
15.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HCI #26135, NCT00708721
|
|
16.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor:
Protocol IDs: EORTC-06061, EORTC-06061, EU-20905, EudraCT-2006-004912-28, GIMEMA-AML-14A, NCT00838240
|
|
17.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 14341B, NCT00943592
|
|
18.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 to 120
Sponsor: Other
Protocol IDs: 090331, NCT00983528
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2005-0536, NCT00299156
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 60 and under
Sponsor: Other
Protocol IDs: 2006-0200, NCT00469014
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLOMDS02507, NCT00531232
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: NCI
Protocol IDs: UMN-2007LS072, UMN-2007LS072, UMN-MT2007-07, NCT00617929
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: iCLO111, NCT00700011
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: GIMEMA-AML-1107, GIMEMA AML1107, EUDRACT-2007-005374-31, EU-20886, WYETH-GIMEMA-AML-1107, NCT00775593
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: 2007-0039, NCT00778375
|
